Ejf Capital Has Upped Keycorp New (KEY) Holding By $1.36 Million; Shorts at Citius Pharmaceuticals (CTXR) Raised By 1900%

KeyCorp (NYSE:KEY) Logo

Citius Pharmaceuticals Inc (NASDAQ:CTXR) had an increase of 1900% in short interest. CTXR’s SI was 14,000 shares in March as released by FINRA. Its up 1900% from 700 shares previously. With 172,100 avg volume, 0 days are for Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s short sellers to cover CTXR’s short positions. The SI to Citius Pharmaceuticals Inc’s float is 0.21%. The stock decreased 5.59% or $0.08 during the last trading session, reaching $1.35. About 88,484 shares traded. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has declined 64.76% since March 14, 2018 and is downtrending. It has underperformed by 69.13% the S&P500. Some Historical CTXR News: 06/03/2018 – CITIUS PHARMACEUTICALS INC – NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID; 06/03/2018 – CITIUS PHARMACEUTICALS – SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS; 06/03/2018 – CITIUS PHARMACEUTICALS – PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001; 06/03/2018 – CITIUS PHARMACEUTICALS INC – HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY; 06/03/2018 Citius Reports Progress in Hemorroid Treatment Program; 06/03/2018 – CITIUS PHARMACEUTICALS INC – REQUESTED FDA’S FEEDBACK ON PHASE 2B STUDY DESIGN; 06/03/2018 – CITIUS PHARMACEUTICALS – MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY

Ejf Capital Llc increased Keycorp New (KEY) stake by 32.45% reported in 2018Q4 SEC filing. Ejf Capital Llc acquired 97,366 shares as Keycorp New (KEY)’s stock declined 6.05%. The Ejf Capital Llc holds 397,440 shares with $5.87M value, up from 300,074 last quarter. Keycorp New now has $17.58B valuation. The stock increased 0.64% or $0.11 during the last trading session, reaching $17.43. About 7.26M shares traded. KeyCorp (NYSE:KEY) has declined 17.86% since March 14, 2018 and is downtrending. It has underperformed by 22.23% the S&P500. Some Historical KEY News: 02/04/2018 – KeyCorp Closes Below 200-Day Moving Average: Technicals; 30/04/2018 – Olin Presenting at KeyCorp Conference May 30; 29/05/2018 – Werner Enterprises Presenting at KeyCorp Conference Tomorrow; 25/05/2018 – Casella Waste Presenting at KeyCorp Conference May 31; 29/03/2018 – PRESS RELEASE – KEYBANK ENTERS INTO AGREEMENT TO SELL KEY INSURANCE & BENEFITS SERVICES, INC. TO USI INSURANCE SERVICES; 21/05/2018 – Rexnord Presenting at KeyCorp Conference May 30; 25/05/2018 – Wabco Presenting at KeyCorp Conference May 31; 30/04/2018 – MRC Global Presenting at KeyCorp Conference May 30; 02/05/2018 – KeyBank Ranked #35 of “Top 50 Companies for Diversity” by DiversityInc; 05/03/2018 Bruce Murphy, Keycorp’s Head Of Corporate Responsibility, To Retire In 2018

More notable recent Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) news were published by: Seekingalpha.com which released: “Citius Pharma up 7% on in-license of anti-infective gel wrap – Seeking Alpha” on January 08, 2019, also Globenewswire.com with their article: “Citius Provides Update on Its CITI Platforms and Gives Investors Further Insight on their Licensing Agreement with MD Anderson Cancer Center – GlobeNewswire” published on February 06, 2019, Seekingalpha.com published: “Promising Developments For Citius Pharma – Seeking Alpha” on September 29, 2017. More interesting news about Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) were released by: Benzinga.com and their article: “Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings – Benzinga” published on November 28, 2018 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings – Benzinga” with publication date: August 09, 2018.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products. The company has market cap of $25.00 million. The firm develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment of catheter related bloodstream infections; and Hydrocortisone-Lidocaine Cream for the treatment of mild to moderate hemorrhoids. It currently has negative earnings. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico.

Ejf Capital Llc decreased Coastal Finl Corp Wa stake by 72,578 shares to 962,453 valued at $14.66M in 2018Q4. It also reduced Sandy Spring Bancorp Inc (NASDAQ:SASR) stake by 50,074 shares and now owns 100,015 shares. Brighthouse Finl Inc was reduced too.

Among 7 analysts covering KeyCorp (NYSE:KEY), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. KeyCorp had 11 analyst reports since September 18, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Wedbush on Monday, February 4. The firm has “Buy” rating by Standpoint Research given on Friday, October 12. BMO Capital Markets maintained it with “Outperform” rating and $21 target in Friday, October 19 report. BMO Capital Markets downgraded KeyCorp (NYSE:KEY) rating on Friday, January 18. BMO Capital Markets has “Market Perform” rating and $17 target. The company was downgraded on Tuesday, November 13 by Nomura. The company was upgraded on Friday, January 11 by Sandler O’Neill. Nomura maintained the stock with “Buy” rating in Friday, October 19 report. Nomura downgraded the shares of KEY in report on Monday, December 10 to “Reduce” rating. The firm earned “Overweight” rating on Tuesday, September 18 by Morgan Stanley. As per Monday, December 3, the company rating was maintained by Citigroup.

More notable recent KeyCorp (NYSE:KEY) news were published by: Seekingalpha.com which released: “KeyCorp’s Digital Efforts Driving Returns And Dividend Growth – Seeking Alpha” on March 10, 2019, also Investorplace.com with their article: “4 Key Questions Facing Spotify Stock – Investorplace.com” published on March 08, 2019, Seekingalpha.com published: “Deere: Why Sales Growth Is Key – Seeking Alpha” on February 18, 2019. More interesting news about KeyCorp (NYSE:KEY) were released by: Forbes.com and their article: “Tax Fraud A Key Role In Major College Admissions Scandal Involving Hollywood Actors, CEOs And More – Forbes” published on March 13, 2019 as well as Benzinga.com‘s news article titled: “Facebook Vs. Twitter Vs. Snapchat: How Do Key Statistics Compare? (NASDAQ:FB)(NYSE:TWTR)(NYSE:SNAP) – Benzinga” with publication date: February 18, 2019.

KeyCorp (NYSE:KEY) Institutional Positions Chart